Advanced Renal Cell Carcinoma Pipeline and Clinical Trials Assessment 2023: FDA Approvals, Therapies and Key Companies involved by DelveInsight | Merck Sharp & Dohme, Chia Tai Tianqing Pharmaceutical, Hoffmann-La Roche, CoImmune, Infinity Pharmaceuticals,

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Advanced Renal Cell Carcinoma pipeline constitutes 40+ key companies continuously working towards developing 40+ Advanced Renal Cell Carcinoma treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Advanced Renal Cell Carcinoma Pipeline Insight, 2023" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Advanced Renal Cell Carcinoma Market.

The Advanced Renal Cell Carcinoma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Advanced Renal Cell Carcinoma Pipeline Report: delveinsight.com/sample-request/advanced-renal-cell-carcinoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Advanced Renal Cell Carcinoma treatment therapies with a considerable amount of success over the years.
• Advanced Renal Cell Carcinoma companies working in the treatment market are Molecure S.A., Daiichi Sankyo, Janux Therapeutics, NiKang Therapeutics, CoImmune, Infinity Pharmaceuticals, Chia Tai TianqingPharmaceutical, Merck Sharp & Dohme, Hoffmann-La Roche, AstraZeneca, Xencor, and others, are developing therapies for the Advanced Renal Cell Carcinoma treatment
• Emerging Advanced Renal Cell Carcinoma therapies in the different phases of clinical trials are- OATD-02, DS-6000a, JANX008, NKT2152, CMN-001, IPI-549, TQB2450, Belzutifa, Atezolizumab, Volrustomig, XmAb819, and others are expected to have a significant impact on the Advanced Renal Cell Carcinoma market in the coming years.
• In July 2023, The Chinese National Medical Products Administration (NMPA) has reviewed a supplemental new drug application (sNDA) aiming to obtain approval for the use of toripalimab (Tuoyi) in combination with axitinib (Inlyta) as a first-line treatment for patients diagnosed with unresectable or metastatic renal cell carcinoma (RCC). This application is backed by data derived from an interim analysis of the phase 3 RENOTORCH trial (NCT04394975), demonstrating that the combined therapy resulted in an enhanced progression-free survival (PFS) compared to the use of the single-agent sunitinib (Sutent).
• In April 2023, During the American Association for Cancer Research (AACR) Annual Meeting in Orlando, Florida, Allogene Therapeutics shared interim findings from its Phase 1 TRAVERSE trial involving ALLO-316, the company's initial AlloCAR T investigational product designed for treating solid tumors. The presented data showcased promising preliminary antitumor effects and a reassuring safety profile of the innovative anti-CD70 allogeneic CAR T-cell therapy, ALLO-316, particularly at lower dosage levels. These results suggest that this regimen could potentially serve as a new treatment option for heavily treated patients diagnosed with advanced clear cell renal cell carcinoma (ccRCC) expressing CD70.
• In April 2023, Shanghai Junshi Biosciences Co., Ltd. has announced the completion of the pre-planned interim analysis for the RENOTORCH trial (NCT04394975). This trial, a phase 3 clinical study, is a multicenter, randomized, open-label investigation assessing the effectiveness of toripalimab combined with axitinib as a first-line treatment for patients diagnosed with intermediate to high-risk, unresectable, or distant metastatic renal cell carcinoma (RCC). The Independent Data Monitoring Committee (IDMC) has confirmed that the primary measure of progression-free survival (PFS), evaluated through an independent radiographic review, has achieved the predefined efficacy threshold.
• In January 2023, Teon Therapeutics revealed a clinical trial collaboration agreement with Merck, specifically focusing on the combination arm of Teon's ongoing clinical study. This study involves two arms, an open-label, dose escalation, and expansion phase. It aims to assess TT-816, Teon's oral immune response modifier, in conjunction with Merck's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), designed for patients grappling with advanced solid tumors.
• In December 2022, Exelixis has launched STELLAR-304, a crucial phase 3 trial designed to assess zanzalintinib in combination with nivolumab compared to sunitinib in individuals diagnosed with advanced non-clear cell renal cell carcinoma (nccRCC).
• In November 2022, The FDA has awarded a fast-track designation to batiraxcept (AVB-S6-500) intended for treating patients with advanced or metastatic clear cell renal cell carcinoma (RCC) who have experienced disease progression after one or two prior lines of systemic therapy. These therapies should have encompassed a combination or sequential use of both immuno-oncology (IO)-based and VEGF TKI-based treatments.
• In March 2022, Merck Sharp & Dohme has commenced a double-blind, randomized Phase III study across multiple centers. The primary objective of this study (MK-6482-022) is to compare the effectiveness and safety of Belzutifan (MK-6482) combined with pembrolizumab (MK-3475) against a placebo combined with pembrolizumab in the adjuvant treatment of clear cell renal cell carcinoma (ccRCC) following nephrectomy.

Advanced Renal Cell Carcinoma Overview
Advanced Renal Cell Carcinoma (RCC) refers to a stage of kidney cancer where the cancer has spread beyond the kidney to other parts of the body. Renal cell carcinoma originates in the lining of small tubes in the kidney and can progress to an advanced stage if it metastasizes or spreads to nearby lymph nodes or distant organs.

Get a Free Sample PDF Report to know more about Advanced Renal Cell Carcinoma Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/advanced-renal-cell-carcinoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Advanced Renal Cell Carcinoma Drugs Under Different Phases of Clinical Development Include:
• OATD-02: Molecure S.A.
• DS-6000a: Daiichi Sankyo
• JANX008: Janux Therapeutics
• NKT2152: NiKang Therapeutics
• CMN-001: CoImmune
• IPI-549: Infinity Pharmaceuticals
• TQB2450: Chia Tai TianqingPharmaceutical
• Belzutifan: Merck Sharp & Dohme
• Atezolizumab: Hoffmann-La Roche
• Volrustomig: AstraZeneca
• XmAb819: Xencor

Advanced Renal Cell Carcinoma Route of Administration
Advanced Renal Cell Carcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical.
• Molecule Type

Advanced Renal Cell Carcinoma Molecule Type
Advanced Renal Cell Carcinoma Products have been categorized under various Molecule types, such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

Advanced Renal Cell Carcinoma Pipeline Therapeutics Assessment
• Advanced Renal Cell Carcinoma Assessment by Product Type
• Advanced Renal Cell Carcinoma By Stage and Product Type
• Advanced Renal Cell Carcinoma Assessment by Route of Administration
• Advanced Renal Cell Carcinoma By Stage and Route of Administration
• Advanced Renal Cell Carcinoma Assessment by Molecule Type
• Advanced Renal Cell Carcinoma by Stage and Molecule Type

DelveInsight's Advanced Renal Cell Carcinoma Report covers around 40+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Advanced Renal Cell Carcinoma product details are provided in the report. Download the Advanced Renal Cell Carcinoma pipeline report to learn more about the emerging Advanced Renal Cell Carcinoma therapies at:
delveinsight.com/sample-request/advanced-renal-cell-carcinoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key companies in the Advanced Renal Cell Carcinoma Therapeutics Market include:
Key companies developing therapies for Advanced Renal Cell Carcinoma are - Merck Sharp & Dohme, Chia Tai Tianqing Pharmaceutical, Hoffmann-La Roche, CoImmune, Infinity Pharmaceuticals, NiKang Therapeutics, Molecure S.A., Daiichi Sankyo, Janux Therapeutics, MedImmune, Eli Lilly and Company, Jiangsu HengRui Medicine Co., Ltd., Allogene Therapeutics, Chongqing Precision Biotech Co., Ltd, Pfizer, Exelixis, BeiGene, Xencor, Teon Therapeutics, Asher Biotherapeutics, Shanghai Junshi Biosciences, Surface Oncology, ProfoundBio, Portage Biotech, Novartis Pharmaceuticals, HiFiBiO, and others.

Advanced Renal Cell Carcinoma Pipeline Analysis:
The Advanced Renal Cell Carcinoma pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Advanced Renal Cell Carcinoma with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Advanced Renal Cell Carcinoma Treatment.
• Advanced Renal Cell Carcinoma key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Advanced Renal Cell Carcinoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Advanced Renal Cell Carcinoma market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Advanced Renal Cell Carcinoma drugs and therapies-
delveinsight.com/sample-request/advanced-renal-cell-carcinoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Advanced Renal Cell Carcinoma Pipeline Market Drivers
• Increasing Prevalence in Advanced Renal Cell Carcinoma, increase in the number of research and development activities are some of the important factors that are fueling the Advanced Renal Cell Carcinoma Market.

Advanced Renal Cell Carcinoma Pipeline Market Barriers
• However, side-effects associated with the treatment of Advanced Renal Cell Carcinoma, cost associated with the treatment and other factors are creating obstacles in the Advanced Renal Cell Carcinoma Market growth.

Scope of Advanced Renal Cell Carcinoma Pipeline Drug Insight
• Coverage: Global
• Key Advanced Renal Cell Carcinoma Companies: Molecure S.A., Daiichi Sankyo, Janux Therapeutics, NiKang Therapeutics, CoImmune, Infinity Pharmaceuticals, Chia Tai TianqingPharmaceutical, Merck Sharp & Dohme, Hoffmann-La Roche, AstraZeneca, Xencor, and others
• Key Advanced Renal Cell Carcinoma Therapies: OATD-02, DS-6000a, JANX008, NKT2152, CMN-001, IPI-549, TQB2450, Belzutifa, Atezolizumab, Volrustomig, XmAb819, and others
• Advanced Renal Cell Carcinoma Therapeutic Assessment: Advanced Renal Cell Carcinoma current marketed and Advanced Renal Cell Carcinoma emerging therapies
• Advanced Renal Cell Carcinoma Market Dynamics: Advanced Renal Cell Carcinoma market drivers and Advanced Renal Cell Carcinoma market barriers

Request for Sample PDF Report for Advanced Renal Cell Carcinoma Pipeline Assessment and clinical trials-
delveinsight.com/sample-request/advanced-renal-cell-carcinoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Advanced Renal Cell Carcinoma Report Introduction
2. Advanced Renal Cell Carcinoma Executive Summary
3. Advanced Renal Cell Carcinoma Overview
4. Advanced Renal Cell Carcinoma- Analytical Perspective In-depth Commercial Assessment
5. Advanced Renal Cell Carcinoma Pipeline Therapeutics
6. Advanced Renal Cell Carcinoma Late Stage Products (Phase II/III)
7. Advanced Renal Cell Carcinoma Mid Stage Products (Phase II)
8. Advanced Renal Cell Carcinoma Early Stage Products (Phase I)
9. Advanced Renal Cell Carcinoma Preclinical Stage Products
10. Advanced Renal Cell Carcinoma Therapeutics Assessment
11. Advanced Renal Cell Carcinoma Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Advanced Renal Cell Carcinoma Key Companies
14. Advanced Renal Cell Carcinoma Key Products
15. Advanced Renal Cell Carcinoma Unmet Needs
16 . Advanced Renal Cell Carcinoma Market Drivers and Barriers
17. Advanced Renal Cell Carcinoma Future Perspectives and Conclusion
18. Advanced Renal Cell Carcinoma Analyst Views
19. Appendix
20. About DelveInsight

Related Reports:

Advanced Renal Cell Carcinoma Market https://www.delveinsight.com/report-store/advanced-renal-cell-carcinoma-rcc-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Advanced Renal Cell Carcinoma Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),

Advanced Renal Cell Carcinoma Epidemiology https://www.delveinsight.com/report-store/advanced-renal-cell-carcinoma-rcc-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Advanced Renal Cell Carcinoma Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports:
Lung Transplant Rejection Market https://www.delveinsight.com/report-store/lung-transplant-rejection-market
DelveInsight's "Lung Transplant Rejection Market Insights, Epidemiology, and Market Forecast - 2032" report delivers an in-depth understanding of the Lung Transplant Rejection, historical and forecasted epidemiology as well as the Lung Transplant Rejection market trends in the United States, EU4 (Germany, France, Italy, Spain), and the United Kingdom, and Japan.

CAR T-Cell Therapy for Multiple Myeloma Market
https://www.delveinsight.com/report-store/car-t-cell-therapy-for-multiple-myeloma-market
DelveInsight's "CAR-T Cell Therapy for Multiple Myeloma Market Insights, Epidemiology and Market Forecast - 2032" report delivers an in-depth understanding of multiple myeloma and various CAR-Ts used in multiple myeloma, and CAR-Ts historical and forecasted market trends in multiple myeloma in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Insulin Resistance Market
https://www.delveinsight.com/report-store/insulin-resistance-market
DelveInsight's "Insulin Resistance Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Insulin Resistance, historical and forecasted epidemiology as well as the Insulin Resistance market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Dyskinesia Market
https://www.delveinsight.com/report-store/dyskinesia-market
DelveInsight's "Dyskinesia Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Dyskinesia, historical and forecasted epidemiology as well as the Dyskinesia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Hemophilia Market
https://www.delveinsight.com/report-store/hemophilia-market
DelveInsight's "Hemophilia Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Hemophilia, historical and forecasted epidemiology as well as the Hemophilia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Paroxysmal Nocturnal Hemoglobinuria Market
https://www.delveinsight.com/report-store/paroxysmal-nocturnal-hemoglobinuria-market
DelveInsight's 'Paroxysmal Nocturnal Hemoglobinuria Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of Paroxysmal Nocturnal Hemoglobinuria historical and forecasted epidemiology as well as the Paroxysmal Nocturnal Hemoglobinuria market trends in the United States, the EU4 (Germany, France, Italy, Spain), the UK and Japan.

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+91-9650213330
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.